Survival in unresectable hepatocellular carcinoma: Comparison of four treatments based on patients reconstructed from Kaplan–Meier curves of randomized trials

doi:10.4292/wjgpt.120377

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 3

This Article

(5)

(8)

(0)

(77)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Pharmacology and Therapeutics

ISSN

2150-5349

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Systematic Reviews

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastrointest Pharmacol Ther. Sep 5, 2026; 17(3): 120377
Published online Sep 5, 2026. doi: 10.4292/wjgpt.120377

Full Size Figure Download Figure

Figure 2 Comparison of overall survival benefit in studies using sorafenib as control arm. In red, the 6 sorafenib control arms pooled together; in gold, camrelizumab + rivoceranib[7]; in light green, tremelimumab + durvalumab[4]; in light blue, cabozantinib + atezolizumab[6]; in dark green, atezolizumab + bevacizumab[3]; in purple, toripalimab + bevacizumab[8]; in pink, anlotinib + penpulimab[10]. Endpoint: Overall survival; time in months.

Citation: Damuzzo V, Vecchia S, Gasperoni L, Del Bono L, Ossato A, Orlandi E, Messori A. Survival in unresectable hepatocellular carcinoma: Comparison of four treatments based on patients reconstructed from Kaplan–Meier curves of randomized trials. World J Gastrointest Pharmacol Ther 2026; 17(3): 120377
URL: https://www.wjgnet.com/2150-5349/full/v17/i3/120377.htm
DOI: https://dx.doi.org/10.4292/wjgpt.120377

Damuzzo V, Vecchia S, Gasperoni L, Del Bono L, Ossato A, Orlandi E, Messori A. Survival in unresectable hepatocellular carcinoma: Comparison of four treatments based on patients reconstructed from Kaplan–Meier curves of randomized trials. World J Gastrointest Pharmacol Ther 2026; 17(3): 120377 [DOI: 10.4292/wjgpt.120377]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.